CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

(e) CASI Pharmaceuticals, Inc. (the “Company”) held its 2018 annual meeting of stockholders (the “Annual Meeting”) on June 11, 2018. At the Annual Meeting, the Company’s stockholders approved amendments to the Company’s 2011 Long-Term Incentive Plan (the “2011 Plan”).

Under the amendments to the 2011 Plan, the number of shares of Common Stock reserved for issuance increased from 14,230,000 to 20,230,000 and the limit on the maximum number of shares of Common Stock that may be granted during any calendar year to any one individual was eliminated. The Company’s executive officers and directors are eligible to receive awards under the 2011 Plan in accordance with the terms and conditions set forth therein. A copy of the 2011 Plan was filed with the Securities and Exchange Commission on April 17, 2018 as Appendix A to the Company’s Definitive Proxy Statement on Schedule14A (the “Proxy Statement”) for the Annual Meeting and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the Company’s stockholders considered and approved three proposals, each of which is described in more detail in the Proxy Statement. The following is a brief description of each matter voted upon at the Annual Meeting, and the final voting results for each matter, including the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter.

Election of Directors. Each of Wei-Wu He, PhD, Ken K. Ren, PhD and Rajesh C. Shrotriya, MD was elected to serve as a member of the Board of Directors for a term expiring at the annual meeting of stockholders as indicated in the Proxy Statement and until his successor is duly elected and qualified, as follows:

Director FOR WITHHELD BROKER NON-VOTES
Wei-Wu He, PhD 57,480,581 986,898 16,845,184
Ken K. Ren, PhD 57,507,626 959,853 16,845,184
Rajesh C. Shrotriya, MD 46,808,582 11,658,897 16,845,184

Approval of amendments to the 2011 Long-Term Incentive Plan. The stockholders voted to approve the amendments to the 2011 Plan, as follows:

FOR 57,340,144
AGAINST 1,102,579
ABSTAIN 24,756
BROKER NON-VOTES 16,845,184

Approval of the issuance of equity compensation to the Company’s Executive Chairman. The stockholders voted to approve the issuance of option grants to the Executive Chairman to Nasdaq Listing Rule 5635(c) and, if applicable, Nasdaq Listing Rule 5635(b), as follows:

FOR 57,440,728
AGAINST 998,487
ABSTAIN 28,264
BROKER NON-VOTES 16,845,184

Ratification of Independent Registered Public Accountants. The stockholders voted to ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018, as follows:

FOR 75,050,096
AGAINST 179,056
ABSTAIN 83,511
BROKER NON-VOTES
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


About CASI PHARMACEUTICALS, INC. (NASDAQ:CASI)

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

An ad to help with our costs